Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

COVID-19 hospitalization risk after outpatient nirmatrelvir/ritonavir use, January to August 2022, North Carolina

Journal of Antimicrobial Chemotherapy(2024)10.1093/jac/dkae042Source: DataRank Database

COVID-19 hospitalization risk after outpatient nirmatrelvir/ritonavir use, January to August 2022, North Carolina is a research paper published in Journal of Antimicrobial Chemotherapy (2024). On theSindex it has a DataRank of 0. It has been cited 4 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access4 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 1.29)OA: bronzeTopics (49)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (11)

David A. Wohl ORCID,William A. Fischer ORCID,Luther A. Bartelt ORCID,David van Duin ORCID,Deana Agil

Live enrichment

PubMed:38380946 PMC:PMC10984939 OpenAlex:https://openalex.org/W4391994743

University of North Carolina at Chapel Hill Center for AIDS Research

Grant: P30 AI50410

NIH

Grant: TL1TR002491

NIH-funded SeroNet Serocenter of Excellence Award

Grant: U54 CA260543

National Institute of Allergy and Infectious Diseases

Grant: T32 AI007001

NIAID NIH HHS

Grant: P30 AI050410

National Center for Advancing Translational Sciences

FWCI

1.29

Citation Percentile

0.8%

Citation Trend

2024

2025

2026

bronzeLicense: https://academic.oup.com/pages/standard-publication-reuse-rights

journalhttps://academic.oup.com/jac/article-pdf/79/4/859/57130927/dkae042.pdf

publisherhttps://academic.oup.com/jac/article-pdf/79/4/859/57130927/dkae042.pdf

journalhttps://doi.org/10.1093/jac/dkae042

repositoryhttps://pubmed.ncbi.nlm.nih.gov/38380946

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/10984939

Fields of Study

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19HumansFemaleOutpatientsCOVID-19North CarolinaCOVID-19 TestingCohort StudiesRitonavirSARS-CoV-2COVID-19 Drug TreatmentHospitalizationAntiviral AgentsLactamsLeucineNitrilesProline

MeSH Terms

COVID-19SARS-CoV-2COVID-19 TestingCOVID-19 Drug TreatmentAntiviral AgentsFemaleHospitalizationHumansLactamsLeucineNitrilesNorth CarolinaOutpatientsProlineCohort StudiesRitonavir

Keywords

RitonavirCoronavirus disease 2019 (COVID-19)Medicine2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Emergency medicineVirologyPandemicBetacoronavirusInternal medicineHuman immunodeficiency virus (HIV)Viral loadAntiretroviral therapyOutbreak

Sustainable Development Goals

SDG 0: Good health and well-being